BioAge Labs (BIOA) Cash from Investing Activities (2024 - 2026)

BioAge Labs has disclosed Cash from Investing Activities across 3 years of filings, most recently posting -$164.5 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 951.81% year-over-year to -$164.5 million; the TTM figure through Jun 2026 stood at -$212.9 million (down 126.54% YoY), while the FY2025 annual figure was -$95.2 million, down 25915.3% from the prior year.
• Cash from Investing Activities came in at -$164.5 million for Q2 2026 at BioAge Labs, down from -$46.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $12.8 million in Q3 2025 to a low of -$164.5 million in Q2 2026.
• Average Cash from Investing Activities over 3 years is -$34.1 million, with a median of -$14.4 million recorded in 2025.
• The largest YoY upside for Cash from Investing Activities was 4310.16% in 2025 against a maximum downside of 55392.31% in 2025.
• Over 3 years, Cash from Investing Activities stood at -$26000.0 in 2024, then slumped by 55392.31% to -$14.4 million in 2025, then plunged by 1040.24% to -$164.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$164.5 million in Q2 2026, -$46.8 million in Q1 2026, and -$14.4 million in Q4 2025.